Cargando…
Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study
Multiple sclerosis (MS) patients receiving natalizumab and who are at risk of developing progressive multifocal leukoencephalopathy (PML) often switch to other high-efficacy disease-modifying therapies including fingolimod as a risk mitigation strategy, which could impact treatment safety and effect...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870332/ https://www.ncbi.nlm.nih.gov/pubmed/35203978 http://dx.doi.org/10.3390/brainsci12020215 |
_version_ | 1784656717373505536 |
---|---|
author | Butzkueven, Helmut Giacomini, Paul S. Cohan, Stanley Ziemssen, Tjalf Sienkiewicz, Daniel Zhang, Ying Geissbühler, Yvonne Silva, Diego Tomic, Davorka Kropshofer, Harald Trojano, Maria |
author_facet | Butzkueven, Helmut Giacomini, Paul S. Cohan, Stanley Ziemssen, Tjalf Sienkiewicz, Daniel Zhang, Ying Geissbühler, Yvonne Silva, Diego Tomic, Davorka Kropshofer, Harald Trojano, Maria |
author_sort | Butzkueven, Helmut |
collection | PubMed |
description | Multiple sclerosis (MS) patients receiving natalizumab and who are at risk of developing progressive multifocal leukoencephalopathy (PML) often switch to other high-efficacy disease-modifying therapies including fingolimod as a risk mitigation strategy, which could impact treatment safety and effectiveness. The TRANSITION study aimed to evaluate the safety of fingolimod over two years in patients with MS after switching from natalizumab in a real-world setting. The safety and effectiveness were assessed by monitoring serious and other adverse events (SAEs, AEs). We assessed effectiveness by recording relapses, Expanded Disability Status Scale (EDSS) scores, and MRI activity. Of 637 patients enrolled, 505 completed the study (mean age, 42 years). Overall, 72.8% and 12.7% experienced AEs and SAEs respectively. The most common AEs were fatigue, headache, and urinary tract infection; no cases of PML were observed. Fingolimod treatment resulted in low disease activity. Patients with ≤8 weeks washout period had a markedly lower risk of relapses (4.5%) than those with >8 weeks (51.4%). In patients switching from natalizumab to fingolimod, no new safety signals with overall low relapse activity were observed in patients with washout latencies of ≤8 weeks before fingolimod initiation. Fingolimod was found to be safe and effective in patients transitioning from natalizumab. |
format | Online Article Text |
id | pubmed-8870332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88703322022-02-25 Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study Butzkueven, Helmut Giacomini, Paul S. Cohan, Stanley Ziemssen, Tjalf Sienkiewicz, Daniel Zhang, Ying Geissbühler, Yvonne Silva, Diego Tomic, Davorka Kropshofer, Harald Trojano, Maria Brain Sci Article Multiple sclerosis (MS) patients receiving natalizumab and who are at risk of developing progressive multifocal leukoencephalopathy (PML) often switch to other high-efficacy disease-modifying therapies including fingolimod as a risk mitigation strategy, which could impact treatment safety and effectiveness. The TRANSITION study aimed to evaluate the safety of fingolimod over two years in patients with MS after switching from natalizumab in a real-world setting. The safety and effectiveness were assessed by monitoring serious and other adverse events (SAEs, AEs). We assessed effectiveness by recording relapses, Expanded Disability Status Scale (EDSS) scores, and MRI activity. Of 637 patients enrolled, 505 completed the study (mean age, 42 years). Overall, 72.8% and 12.7% experienced AEs and SAEs respectively. The most common AEs were fatigue, headache, and urinary tract infection; no cases of PML were observed. Fingolimod treatment resulted in low disease activity. Patients with ≤8 weeks washout period had a markedly lower risk of relapses (4.5%) than those with >8 weeks (51.4%). In patients switching from natalizumab to fingolimod, no new safety signals with overall low relapse activity were observed in patients with washout latencies of ≤8 weeks before fingolimod initiation. Fingolimod was found to be safe and effective in patients transitioning from natalizumab. MDPI 2022-02-04 /pmc/articles/PMC8870332/ /pubmed/35203978 http://dx.doi.org/10.3390/brainsci12020215 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Butzkueven, Helmut Giacomini, Paul S. Cohan, Stanley Ziemssen, Tjalf Sienkiewicz, Daniel Zhang, Ying Geissbühler, Yvonne Silva, Diego Tomic, Davorka Kropshofer, Harald Trojano, Maria Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study |
title | Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study |
title_full | Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study |
title_fullStr | Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study |
title_full_unstemmed | Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study |
title_short | Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study |
title_sort | safety of fingolimod in patients with multiple sclerosis switched from natalizumab: results from transition―a 2-year, multicenter, observational, cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870332/ https://www.ncbi.nlm.nih.gov/pubmed/35203978 http://dx.doi.org/10.3390/brainsci12020215 |
work_keys_str_mv | AT butzkuevenhelmut safetyoffingolimodinpatientswithmultiplesclerosisswitchedfromnatalizumabresultsfromtransitiona2yearmulticenterobservationalcohortstudy AT giacominipauls safetyoffingolimodinpatientswithmultiplesclerosisswitchedfromnatalizumabresultsfromtransitiona2yearmulticenterobservationalcohortstudy AT cohanstanley safetyoffingolimodinpatientswithmultiplesclerosisswitchedfromnatalizumabresultsfromtransitiona2yearmulticenterobservationalcohortstudy AT ziemssentjalf safetyoffingolimodinpatientswithmultiplesclerosisswitchedfromnatalizumabresultsfromtransitiona2yearmulticenterobservationalcohortstudy AT sienkiewiczdaniel safetyoffingolimodinpatientswithmultiplesclerosisswitchedfromnatalizumabresultsfromtransitiona2yearmulticenterobservationalcohortstudy AT zhangying safetyoffingolimodinpatientswithmultiplesclerosisswitchedfromnatalizumabresultsfromtransitiona2yearmulticenterobservationalcohortstudy AT geissbuhleryvonne safetyoffingolimodinpatientswithmultiplesclerosisswitchedfromnatalizumabresultsfromtransitiona2yearmulticenterobservationalcohortstudy AT silvadiego safetyoffingolimodinpatientswithmultiplesclerosisswitchedfromnatalizumabresultsfromtransitiona2yearmulticenterobservationalcohortstudy AT tomicdavorka safetyoffingolimodinpatientswithmultiplesclerosisswitchedfromnatalizumabresultsfromtransitiona2yearmulticenterobservationalcohortstudy AT kropshoferharald safetyoffingolimodinpatientswithmultiplesclerosisswitchedfromnatalizumabresultsfromtransitiona2yearmulticenterobservationalcohortstudy AT trojanomaria safetyoffingolimodinpatientswithmultiplesclerosisswitchedfromnatalizumabresultsfromtransitiona2yearmulticenterobservationalcohortstudy |